Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutic (NQ: HALO )

41.33 USD +0.26 (+0.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 682,179
Open 40.98
Bid (Size) 40.00 (1)
Ask (Size) 42.50 (1)
Prev. Close 41.07
Today's Range 40.90 - 41.98
52wk Range 25.17 - 56.40
Shares Outstanding 142,385,930
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Halozyme to Participate in Canaccord Genuity 41st Annual Growth Conference
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine Sun, senior vice president and chief financial officer, will virtually represent the company in a fireside chat at the Canaccord... 
From PR Newswire
Halozyme To Host Second Quarter 2021 Financial Results Webcast and Conference Call
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2021 on Monday, August 9 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president... 
From PR Newswire

Performance

YTD
-2.55%
-2.55%
1 Month
-8.98%
-8.98%
3 Month
-17.26%
-17.26%
6 Month
-13.15%
-13.15%
1 Year
+50.29%
+50.29%

More News

Read More
Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Aft
From PR Newswire
Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple
From PR Newswire
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV
From PR Newswire
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
From Business Wire News Releases
Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE® at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
From PR Newswire
Halozyme to Present at Upcoming Investor Conferences
From PR Newswire
Interesting HALO Put And Call Options For March 2022
Tags Stocks
From Market News Video
Analyzing Halozyme Therapeutics's Unusual Options Activity
Tags Markets Benzinga Market News
From Benzinga
Janssen's Darzalex Faspro Wins FDA Approval In Combination With Pomalidomide, Dexamethasone For Multiple Myeloma
Tags News Briefs FDA
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.